Our focus is on diseases which are modulated by the host immune response. We use a virtual biotech model to identify clinical-stage assets for high-value development which is designed to unlock major benefits for both patients and shareholders. Where possible, we leverage our investor capital with non-dilutive funding by directing our effort at disease targets with high national strategic value.

IMPLICIT AND CMC ICOS ANNOUNCE IC14 MANUFACTURING AGREEMENT AND PATENT LICENSE

8 May 2009

Implicit Bioscience Ltd and CMC ICOS Biologics today announced the execution of a manufacturing contract to support the next stage of development and commercialization of IC14, a clinical-stage monoclonal antibody for acute lung injury (ALI). ...(click here to read more)